ID_events | cancer | TypeID | ImmuneCell | P | R | CorrelationPlot |
ENSG00000234420.6,ZNF37BP | BLCA | EAG | Macrophages_M0 | 1.9461e-02 | 0.2501 |  |
chr10:42515982-42516283:- | BRCA | EER | T_cells_CD4_naive | 2.7398e-03 | 0.1394 |  |
ENSG00000234420.6,ZNF37BP | BRCA | EAG | T_cells_CD4_naive | 3.2587e-02 | 0.0894 |  |
ENSG00000234420.6,ZNF37BP | CESC | EAG | Neutrophils | 1.1703e-03 | 0.3523 |  |
chr10:42517841-42518872:- | COAD | EER | NK_cells_resting | 2.4968e-03 | -0.4069 |  |
ENSG00000234420.6,ZNF37BP | COAD | EAG | T_cells_CD4_memory_activated | 3.6844e-03 | -0.3292 |  |
chr10:42517841-42518872:- | ESCA | EER | Eosinophils | 4.4176e-02 | 0.2271 |  |
chr10:42517841-42518872:- | HNSC | EER | NK_cells_activated | 4.6237e-02 | 0.3667 |  |
ENSG00000234420.6,ZNF37BP | HNSC | EAG | Plasma_cells | 4.8262e-02 | 0.3363 |  |
ENSG00000234420.6,ZNF37BP | LAML | EAG | T_cells_CD4_naive | 3.2593e-02 | -0.2150 |  |
chr10:42517841-42518872:- | LGG | EER | Dendritic_cells_activated | 1.5488e-03 | 0.1741 |  |
ENSG00000234420.6,ZNF37BP | LGG | EAG | T_cells_regulatory_(Tregs) | 4.3357e-03 | 0.1404 | .ENSG00000234420.6,ZNF37BP.png) |
ENSG00000234420.6,ZNF37BP | LUAD | EAG | NK_cells_resting | 1.4815e-02 | 0.2248 |  |
chr10:42517841-42518872:- | LUSC | EER | Macrophages_M1 | 3.3055e-02 | -0.2498 |  |
chr10:42517841-42518872:- | PCPG | EER | Macrophages_M2 | 2.4120e-03 | -0.3110 |  |
ENSG00000234420.6,ZNF37BP | PCPG | EAG | Macrophages_M2 | 2.4596e-02 | -0.2018 |  |
ENSG00000234420.6,ZNF37BP | PRAD | EAG | T_cells_CD8 | 9.0576e-03 | -0.2255 |  |
chr10:42517841-42518872:- | SARC | EER | Plasma_cells | 3.3558e-02 | 0.3828 |  |
chr10:42517841-42518872:- | SKCM | EER | B_cells_memory | 3.3117e-02 | 0.1870 |  |
ENSG00000234420.6,ZNF37BP | SKCM | EAG | B_cells_memory | 8.5865e-03 | 0.2046 |  |
chr10:42517841-42518872:- | STAD | EER | T_cells_CD8 | 1.4299e-02 | 0.1854 |  |
ENSG00000234420.6,ZNF37BP | STAD | EAG | T_cells_CD4_memory_activated | 9.8352e-03 | 0.1822 |  |
ENSG00000234420.6,ZNF37BP | UCEC | EAG | Macrophages_M1 | 2.8909e-03 | -0.4341 |  |
ID_events | cancer | HallmarkType | Type | P | R | CorrelationPlot |
ENSG00000234420.6,ZNF37BP | BLCA | GSVA_HALLMARK_ANDROGEN_RESPONSE | EAG | 1.2869e-02 | 0.2657 |  |
ENSG00000234420.6,ZNF37BP | BRCA | GSVA_HALLMARK_XENOBIOTIC_METABOLISM | EAG | 4.4870e-03 | 0.1188 |  |
chr10:42517841-42518872:- | BRCA | GSVA_HALLMARK_FATTY_ACID_METABOLISM | EER | 3.0294e-03 | 0.1384 |  |
chr10:42515982-42516283:- | BRCA | GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY | EER | 1.2260e-10 | 0.2942 |  |
ENSG00000234420.6,ZNF37BP | CESC | GSVA_HALLMARK_P53_PATHWAY | EAG | 1.2816e-02 | -0.2738 |  |
ENSG00000234420.6,ZNF37BP | COAD | GSVA_HALLMARK_SPERMATOGENESIS | EAG | 4.9707e-02 | -0.2259 |  |
chr10:42517841-42518872:- | COAD | GSVA_HALLMARK_HEDGEHOG_SIGNALING | EER | 3.4195e-02 | 0.2915 |  |
chr10:42515982-42516283:- | ESCA | GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY | EER | 1.0536e-02 | 0.2761 |  |
ENSG00000234420.6,ZNF37BP | ESCA | GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION | EAG | 8.0132e-03 | -0.2638 |  |
ENSG00000234420.6,ZNF37BP | GBM | GSVA_HALLMARK_UV_RESPONSE_DN | EAG | 8.2001e-03 | 0.3329 |  |
chr10:42517841-42518872:- | GBM | GSVA_HALLMARK_UV_RESPONSE_DN | EER | 1.3517e-02 | 0.4025 |  |
chr10:42517841-42518872:- | HNSC | GSVA_HALLMARK_ALLOGRAFT_REJECTION | EER | 2.8075e-02 | -0.4010 |  |
ENSG00000234420.6,ZNF37BP | KIRP | GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE | EAG | 3.3431e-02 | -0.2564 |  |
ENSG00000234420.6,ZNF37BP | LGG | GSVA_HALLMARK_XENOBIOTIC_METABOLISM | EAG | 6.7067e-05 | 0.1953 |  |
chr10:42517841-42518872:- | LGG | GSVA_HALLMARK_HEDGEHOG_SIGNALING | EER | 2.0852e-04 | -0.2034 |  |
ENSG00000234420.6,ZNF37BP | LUAD | GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE | EAG | 1.4194e-03 | -0.2917 |  |
chr10:42517841-42518872:- | LUAD | GSVA_HALLMARK_APICAL_SURFACE | EER | 1.7251e-04 | -0.4232 |  |
chr10:42517841-42518872:- | OV | GSVA_HALLMARK_MITOTIC_SPINDLE | EER | 2.3886e-02 | -0.2193 |  |
ENSG00000234420.6,ZNF37BP | PAAD | GSVA_HALLMARK_APICAL_JUNCTION | EAG | 2.1368e-02 | 0.3722 |  |
ENSG00000234420.6,ZNF37BP | PCPG | GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE | EAG | 2.6103e-02 | -0.1998 |  |
chr10:42517841-42518872:- | PCPG | GSVA_HALLMARK_PANCREAS_BETA_CELLS | EER | 3.9175e-02 | 0.2143 |  |
ENSG00000234420.6,ZNF37BP | PRAD | GSVA_HALLMARK_MYOGENESIS | EAG | 3.8933e-02 | 0.1793 |  |
ENSG00000234420.6,ZNF37BP | READ | GSVA_HALLMARK_UV_RESPONSE_DN | EAG | 1.2844e-02 | 0.5213 |  |
chr10:42517841-42518872:- | SARC | GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY | EER | 3.6329e-04 | 0.5997 |  |
ENSG00000234420.6,ZNF37BP | SARC | GSVA_HALLMARK_APICAL_SURFACE | EAG | 3.5367e-04 | 0.4532 |  |
chr10:42517841-42518872:- | SKCM | GSVA_HALLMARK_KRAS_SIGNALING_DN | EER | 1.7507e-02 | 0.2081 |  |
ENSG00000234420.6,ZNF37BP | SKCM | GSVA_HALLMARK_APICAL_SURFACE | EAG | 2.9581e-02 | 0.1700 |  |
chr10:42517841-42518872:- | STAD | GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING | EER | 3.2964e-02 | -0.1618 |  |
ENSG00000234420.6,ZNF37BP | THCA | GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY | EAG | 2.4544e-03 | 0.2665 |  |
ENSG00000234420.6,ZNF37BP | THYM | GSVA_HALLMARK_HYPOXIA | EAG | 9.5557e-04 | 0.4912 |  |
ENSG00000234420.6,ZNF37BP | UCEC | GSVA_HALLMARK_ALLOGRAFT_REJECTION | EAG | 1.1576e-03 | -0.4689 |  |
ID_events | cancer | Drug | Type | P | R | CorrelationPlot |
ENSG00000234420.6,ZNF37BP | BLCA | AS601245 | EAG | 1.8472e-02 | 0.2521 |  |
chr10:42517841-42518872:- | BRCA | AZ628 | EER | 4.5738e-03 | -0.1324 |  |
ENSG00000234420.6,ZNF37BP | BRCA | AZ628 | EAG | 1.5387e-02 | -0.1014 |  |
chr10:42515982-42516283:- | BRCA | A.770041 | EER | 6.1819e-05 | -0.1861 |  |
ENSG00000234420.6,ZNF37BP | CESC | Lapatinib | EAG | 9.3714e-04 | 0.3587 |  |
chr10:42517841-42518872:- | COAD | Dasatinib | EER | 8.6634e-03 | -0.3571 |  |
ENSG00000234420.6,ZNF37BP | ESCA | AMG.706 | EAG | 1.8474e-03 | 0.3076 |  |
chr10:42515982-42516283:- | ESCA | MG.132 | EER | 1.6059e-03 | -0.3371 |  |
chr10:42517841-42518872:- | ESCA | GW.441756 | EER | 2.9498e-02 | 0.2451 |  |
chr10:42517841-42518872:- | GBM | Cyclopamine | EER | 4.5107e-02 | -0.3314 |  |
ENSG00000234420.6,ZNF37BP | HNSC | GSK.650394 | EAG | 6.8795e-03 | 0.4486 |  |
chr10:42517841-42518872:- | HNSC | Bryostatin.1 | EER | 2.4078e-04 | -0.6223 |  |
ENSG00000234420.6,ZNF37BP | KIRP | CI.1040 | EAG | 9.5592e-03 | 0.3099 |  |
ENSG00000234420.6,ZNF37BP | LAML | FTI.277 | EAG | 4.3563e-02 | 0.2033 |  |
ENSG00000234420.6,ZNF37BP | LGG | Metformin | EAG | 1.1499e-10 | -0.3110 |  |
chr10:42517841-42518872:- | LGG | Metformin | EER | 2.3441e-06 | -0.2573 |  |
ENSG00000234420.6,ZNF37BP | LUAD | Cyclopamine | EAG | 2.0635e-02 | 0.2138 |  |
chr10:42517841-42518872:- | LUAD | ABT.888 | EER | 8.9646e-03 | -0.3018 |  |
chr10:42517841-42518872:- | LUSC | Axitinib | EER | 4.3912e-03 | -0.3297 |  |
ENSG00000234420.6,ZNF37BP | LUSC | Axitinib | EAG | 6.3937e-05 | -0.3624 |  |
ENSG00000234420.6,ZNF37BP | MESO | AMG.706 | EAG | 3.9010e-03 | -0.5110 |  |
ENSG00000234420.6,ZNF37BP | OV | BMS.509744 | EAG | 6.7021e-03 | -0.2220 |  |
chr10:42517841-42518872:- | OV | Gefitinib | EER | 5.0277e-03 | -0.2706 |  |
ENSG00000234420.6,ZNF37BP | PCPG | AICAR | EAG | 5.9034e-03 | 0.2459 |  |
chr10:42517841-42518872:- | PCPG | Cisplatin | EER | 4.8250e-04 | 0.3549 |  |
ENSG00000234420.6,ZNF37BP | PRAD | Imatinib | EAG | 3.6153e-02 | -0.1819 |  |
ENSG00000234420.6,ZNF37BP | READ | CCT007093 | EAG | 3.8824e-02 | -0.4432 |  |
chr10:42517841-42518872:- | SARC | DMOG | EER | 4.5890e-03 | -0.4955 |  |
ENSG00000234420.6,ZNF37BP | SARC | BMS.536924 | EAG | 2.1971e-04 | -0.4670 |  |
chr10:42517841-42518872:- | SKCM | AZD7762 | EER | 5.5958e-03 | -0.2426 |  |
ENSG00000234420.6,ZNF37BP | SKCM | AZD7762 | EAG | 4.3469e-03 | -0.2223 |  |
ENSG00000234420.6,ZNF37BP | STAD | MG.132 | EAG | 1.2730e-02 | -0.1759 |  |
chr10:42517841-42518872:- | STAD | MG.132 | EER | 7.8108e-03 | -0.2010 |  |
ENSG00000234420.6,ZNF37BP | TGCT | JW.7.52.1 | EAG | 1.9749e-02 | 0.3923 |  |
ENSG00000234420.6,ZNF37BP | THCA | Metformin | EAG | 1.2716e-03 | 0.2829 |  |
ENSG00000234420.6,ZNF37BP | THYM | Doxorubicin | EAG | 3.4972e-02 | 0.3263 |  |
ENSG00000234420.6,ZNF37BP | UCEC | Gefitinib | EAG | 2.7926e-02 | 0.3278 |  |